Longitudinal Analyses of Healthcare Resource Utilization and Costs Among Patients With Obstructive Hypertrophic Cardiomyopathy

Impact of Disease Progression on Healthcare Resource Utilization and Quality of Life in Patients With Hypertrophic Cardiomyopathy: A Real-World Cross-Sectional Survey

Lactate Dehydrogenase (LDH) and Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial

The Effect of Aficamten vs Metoprolol on Cardiac Biomarkers in Obstructive Hypertrophic Cardiomyopathy: A Secondary Analysis From MAPLE-HCM

Semiquantitative Urine Dipstick Protein Assessments Predict Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial

Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM

Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial

Clinical Responses to Aficamten Monotherapy Compared with Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis

Chronic Aficamten Treatment Results in Sustained Favorable Cardiac Remodeling in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the FOREST-HCM Trial